证券代码：600488 证券简称：津药药业 编号：2025-048 三、同类药品市场情况 根据米内网全国放大版的医院数据（含城市公立医院、县级公立医院、城市药店、网上药店、城市社区 医院、乡镇卫生院）显示，2023年、2024年腹膜透析液（乳酸盐-G1.5%）国内销售额为15.48亿元、 16.89亿元。2023年、2024年腹膜透析液（乳酸盐-G2.5%）国内销售额为7.43亿元、8.40亿元。 四、影响及风险提示 根据国家相关政策规定，对于通过一致性评价的药品品种，在医保支付方面予以适当支持，医疗机构应 优先采购并在临床中优先选用。津药和平腹膜透析液（乳酸盐）通过一致性评价，有利于提升该药品的 市场竞争力。由于药品研发、生产和销售容易受到国家政策、市场环境等因素影响，具有较大不确定 性，敬请广大投资者谨慎决策，注意防范投资风险。 津药药业股份有限公司关于子公司药品通过仿制药一致性评价的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担个别及连带责任。 近日，津药药业股份有限公司（以下简称"公司"）子公司津药和平（天津）制药有限公司 ...

Core Viewpoint - Tianyao Pharmaceutical's subsidiary Tianyao Heping has received approval for two types of peritoneal dialysis solutions, which will enhance the company's market competitiveness in this product line [1][2]. Group 1: Product Approval and Market Impact - Tianyao Heping's peritoneal dialysis solutions (lactate-G1.5% and lactate-G2.5%) have passed the consistency evaluation for generic drugs, allowing them to be marketed [1]. - The domestic sales forecast for lactate-G1.5% is projected to be 1.548 billion yuan in 2023 and 1.689 billion yuan in 2024, while lactate-G2.5% is expected to generate sales of 743 million yuan in 2023 and 840 million yuan in 2024 [1]. - The approval will lead to appropriate support in medical insurance payments and priority procurement by medical institutions [1]. Group 2: Company Strategy and Development - The company is committed to an integrated development strategy of raw materials and formulations, focusing on steroid hormones and amino acid raw materials [2]. - Tianyao Pharmaceutical has made significant progress in new product research and development, consistency evaluation, and drug registration, with 32 products passing the consistency evaluation and 18 obtaining drug registration certificates [2]. - Several key formulation products have achieved annual sales exceeding 100 million yuan [2].

证券日报网讯 7月29日晚间，津药药业发布公告称，近日，公司子公司津药和平（天津）制药有限公司 收到国家药品监督管理局核准签发的腹膜透析液（乳酸盐）（以下简称"本品"）的《药品补充申请批准 通知书》，批准本品通过仿制药质量和疗效一致性评价（简称"一致性评价"）。 （编辑 楚丽君） ...

Group 1 - Anhui Construction won a joint bid for the Chongqing Rongchang to Sichuan Zigong expressway project, with a total estimated investment of 3.614 billion yuan and a construction period of 3 years [1] - Hongfa Co. reported a net profit of 964 million yuan for the first half of 2025, a year-on-year increase of 14.19%, with revenue of 8.347 billion yuan, up 15.43% [1][2] - Lujiazui's net profit for the first half of 2025 was 815 million yuan, a decrease of 7.87%, despite a revenue increase of 33.91% to 6.598 billion yuan [3] - Enhua Pharmaceutical achieved a net profit of 700 million yuan, up 11.38%, with revenue of 3.010 billion yuan, an increase of 8.93% [4][5] - China CNR signed several major contracts totaling approximately 32.92 billion yuan, covering various sectors including urban rail vehicles and wind power equipment [6] - WanTong Intelligent signed an exclusive sales and cooperation agreement in the embodied intelligence field, gaining global sales rights for specific chip-based products [7][8] Group 2 - Liansheng Technology's subsidiary received a government subsidy of 13.5 million yuan, accounting for 12.24% of the company's latest audited net profit [9] - Guobang Pharmaceutical reported a net profit of 456 million yuan, a year-on-year increase of 12.60%, with revenue of 3.026 billion yuan, up 4.63% [10] - Baotai expects a net loss of 110 to 140 million yuan for the first half of 2025, a reduction in loss compared to the previous year [11] - Sains expects a net profit decrease of 57.53% to 60.13%, with projected revenue growth of 15.17% to 23.59% [12] - Nanya New Materials anticipates a net profit of 80 to 95 million yuan for the first half of 2025, an increase compared to the previous year [13] - Tian Pharmaceutical's subsidiary passed the consistency evaluation for a peritoneal dialysis solution [14] Group 3 - Shede Liquor announced the resignation of director Ni Qiang due to work reasons [15] - Greentown Water plans to transfer assets and liabilities of its ASEAN subsidiary to improve resource allocation [16] - Beibu Gulf Port's subsidiary signed an associated transaction contract worth 11.199 million yuan [17] - Beibu Gulf Port announced multiple resignations of directors and executives [18] - Jidian Co. reported the resignation of its deputy general manager due to work changes [19] - Wanhua Chemical's industrial park in Fujian resumed production after maintenance [20] Group 4 - Shanghai Pharmaceuticals received approval for a clinical trial of a new indication for its B019 injection [21] - Jianbang Co. reported a net profit of 69.66 million yuan, a decrease of 27.72%, with revenue of 307 million yuan, down 15.37% [23] - Jianbang Co. plans to use up to 400 million yuan of idle funds for cash management [25] - Wanfu Bio's subsidiary obtained multiple medical device registrations [28] - Hunan Tianyan announced a change in its controlling shareholder to China Chang'an Automobile Group [29][30] - Xizhuang Co. plans to establish a joint venture for sustainable aviation fuel [32]

关于子公司药品通过仿制药一致性评价的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 近日，津药药业股份有限公司（以下简称"公司"）子公司津药和平（天津）制药有 限公司（以下简称"津药和平"）收到国家药品监督管理局核准签发的腹膜透析液（乳酸 盐）（以下简称 "该药品"或"本品"）的《药品补充申请批准通知书》，批准本品通过 仿制药质量和疗效一致性评价（以下简称"一致性评价"）。现将相关情况公告如下： | 药品名称 | 腹膜透析液（乳酸盐-G1.5%） | 腹膜透析液（乳酸盐-G2.5%） | | --- | --- | --- | | 剂型 | 注射剂 | 注射剂 | | 注册分类 | 化学药品 | 化学药品 | | 药品注册标准编号 | YBH18532025 | YBH18502025 | | 规格 | 2000ml（含 1.5%葡萄糖） | 2000ml（含 2.5%葡萄糖） | | 受理号 | CYHB2450339 | CYHB2450338 | | 通知书编号 | 2025B03432 | 2025B034 ...

Core Insights - The event highlighted the high-quality development of brands in Shandong, emphasizing innovation as a key driver for growth and the integration of manufacturing processes and product connections [1] Company Summaries - **Furida**: Focuses on creating skincare products tailored for Chinese consumers, having developed the first domestic hyaluronic acid essence and a series of micro-ecological skincare products. The company holds over 170 patents and has achieved a sales scale of 1 billion yuan within five years [2] - **Hisense**: After ten years of development, Hisense has successfully created the RGB-Mini LED technology, with a key component being the "Xin Chip H7," which offers three times the light control precision of traditional LCDs. This innovation has positioned Hisense as a leader in display technology [3] - **Huaguang Guoci**: Innovates in high-end ceramics, developing various advanced materials and techniques, including lead-free glazes and antibacterial glazes, while promoting traditional Chinese culture through brand initiatives [4] - **Luhua**: Invests heavily in R&D to produce high-oleic peanuts, achieving over 75% oleic acid content. The company’s unique 5S physical pressing process enhances nutritional retention and flavor, contributing to the agricultural sector's growth [4] Industry Trends - The "chain development" model in Shandong is fostering growth not only for individual companies but also for the entire industry chain, with Hisense leading investments in 25 companies in 2024 and 28 in 2025 [5] - Furida is establishing a multi-brand group operation and a dual beauty ecosystem, with a projected annual output value of 4 billion yuan from its new innovation park [5] - Luhua's approach extends from edible oils to agricultural products, creating a full industry chain that enhances both economic and ecological benefits [6] - The collective efforts of these companies illustrate Shandong's commitment to high-quality development through technological strength, brand enhancement, and ecological synergy, with an increasing number of Shandong brands gaining international recognition [6]

Core Viewpoint - Tianjin Pharmaceutical Co., Ltd. is undergoing significant changes in its operational scope, governance structure, and company charter, which require shareholder approval for implementation [1][2][3]. Summary by Sections Changes in Business Scope - The company plans to expand its business scope to include drug import and export, technology import and export, import and export agency, and goods import and export [2][3]. - The revised business scope includes: - License items: drug production, drug commissioned production, veterinary drug production, cosmetic production, food additive production, feed additive production, hazardous chemical operation, special equipment design, and drug import and export [2][3][4]. - General items: investment activities with self-owned funds, technical services, technical development, technical consulting, technical exchange, technical transfer, technical promotion, traditional Chinese medicine extraction, special chemical product manufacturing (excluding hazardous chemicals), and sales of special chemical products [2][3][4]. Amendments to the Company Charter - The company charter has been revised to align with the Company Law and other relevant regulations, with key changes including: - The first article emphasizes the protection of the rights and interests of the company, shareholders, and creditors [3][4]. - The second article clarifies the founding entities of the company [3][4]. - The eighth article specifies that the general manager is the legal representative of the company, and upon resignation, a new legal representative must be appointed within 30 days [4][5]. - The ninth article introduces provisions regarding the legal consequences of actions taken by the legal representative [4][5]. - The twelfth article outlines the company's operational purpose, focusing on innovation and the integration of high technology and economies of scale [6][7]. Governance Structure Changes - The company will abolish the supervisory board, and the current supervisors will be relieved of their duties upon shareholder approval of the relevant proposals [1][2]. - The company expresses gratitude to the supervisory board and all supervisors for their contributions during their tenure [2][3]. Shareholder Meeting and Approval - The proposed changes will be submitted for approval at the upcoming shareholder meeting, and the current supervisory board will continue to fulfill its supervisory duties until the changes are officially enacted [1][2].

津药药业股份有限公司 股东会议事规则 （已经 2025 年 7 月 25 日第九届董事会第十九次会议审议通过） 第一章 总 则 第一条 为维护津药药业股份有限公司（以下简称"公司"） 及股东的合法权益，保证股东会依法行使职权，根据《中华人民 共和国公司法》（以下简称"《公司法》"）《中华人民共和国证券法》 （以下简称"《证券法》"）《上市公司股东会规则》（以下简称《规 则》）和《津药药业股份有限公司章程》（以下简称《公司章程》） 以及国家的相关法规，制定本规则。 第二条 本公司股东会的召集、提案、通知、召开等事项适用 本规则。 第三条 公司应当严格按照法律、行政法规、《规则》及《公 司章程》的相关规定召开股东会，保证股东能够依法行使权利。 公司董事会应当切实履行职责，认真、按时组织股东会。公 司全体董事应当勤勉尽责，确保股东会正常召开和依法行使职权。 第四条 公司股东会由全体股东组成。股东会应当在《公司法》 和《公司章程》规定的范围内行使职权。股东会是公司的权力机 构，依法行使下列职权： （一）选举和更换董事，决定有关董事的报酬事项； （二）审议批准董事会的报告； （三）审议批准公司的利润分配方案和弥补亏损方 ...

二○二五年七月 （2025年7月25日经公司第九届董事会第十九次会议审议通过） 1 / 49 津药药业 公司章程 津药药业股份有限公司章程 第一章 总 则 第一条 为维护公司、股东、职工和债权人的合法权益，规范公司的组织和 行为，根据《中国共产党章程》（以下简称《党章》）、《中华人民共和国公司 法》（以下简称《公司法》）、《中华人民共和国证券法》（以下简称《证券法》） 和其他有关规定，制定本章程。 第二条 公司系依照《公司法》和其他有关规定，由天津药业集团有限公司、 天津新技术产业园区科技发展有限公司、天津市中央药业有限公司、天津达仁堂 制药厂、天津市药品包装印刷厂共五家发起人以发起方式成立的股份有限公司 （以下简称"公司"）。 | | 1 | | --- | --- | | 1 | | | | 2 | | 第一节 | | 股份发行 | 7 | | --- | --- | --- | --- | | 第二节 | | 股份增减和回购 | 8 | | 第三节 | | 股份转让 | 10 | | 第一节 | | 股东的一般规定 | 11 | | 第二节 | | 控股股东和实际控制人 | 14 | | 第三节 | | ...

证券代码：600488 证券简称：津药药业 编号：2025-046 津药药业股份有限公司 关于变更经营范围、取消监事会、修订《公司章程》 及部分治理制度并办理工商变更的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 津药药业股份有限公司（以下简称"公司"）于 2025 年 7 月 25 日召开第九届董事会第十九次会议，审议通过了《关于变更经营范围、 取消监事会、修订<津药药业股份有限公司章程>并办理工商变更的议 案》以及修订部分治理制度的议案。召开第九届监事会第十四次会议 审议通过了《关于变更经营范围、取消监事会、修订<津药药业股份 有限公司章程>并办理工商变更的议案》。以上议案需提交公司股东大 会审议。 上述议案经股东大会审议通过之日起公司现任监事解除监事职 务，同时公司《监事会议事规则》等监事会相关制度将予以废止。在 此之前，公司第九届监事会仍将按照《中华人民共和国公司法》（以 下简称"《公司法》"）、《津药药业股份有限公司章程》（以下简称"《公 司章程》"）等相关规定勤勉尽责，履行监督职能，维护公司和全体股 ...